Home Newsfeeds Baird Maintains Outperform on Lattice Semiconductor, Raises Price Target to $100

Baird Maintains Outperform on Lattice Semiconductor, Raises Price Target to $100

Baird analyst Tristan Gerra maintains Lattice Semiconductor (NASDAQ:LSCC) with a Outperform and raises the price target from $75 to $100.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Baird analyst Tristan Gerra maintains Lattice Semiconductor (NASDAQ:LSCC) with a Outperform and raises the price target from $75 to $100.

Citigroup Maintains Buy on Instructure Holdings, Raises Price Target to $32

By Benzinga Newsdesk

February 15, 9:26 AM

Citigroup analyst Steven Enders maintains Instructure Holdings (NYSE:INST) with a Buy and raises the price target from $28 to $32.

INST

Axsome Therapeutics Announces Plans To Resubmit AXS-07 NDA Based On Successful FDA Type A Meeting; No Additional Clinical Efficacy Or Safety Trials Have Been Requested By The FDA For A Resubmission Of The NDA

By Benzinga Newsdesk

September 29, 7:12 AM

- Reuters

AXSM

Chevron Reportedly Exploring Option To Sell East Texas Assets: Report

By Lekha Gupta

November 15, 10:11 AM

Energy giant Chevron Corp (NYSE: CVX) is reportedly evaluating sale options for its East Texas assets. The asset comprises around 70,000 net acres of land in East Texas' Haynesville shale formation, for which development was stopped earlier this year, as per Reuters.

CVX

Chamath Palihapitiya Calls Out Warren Buffett’s Japanese Investments: Is He Throwing Shade Or Praising The Legendary Investor?

By Chris Katje

June 22, 12:10 PM

One of the most well-known investors of all time is seeing his recent investment activity called out by a more recent well-known investor. Are the comments praise or an attempt to take on his legacy?

BRK-A

Baird Maintains Outperform on Lattice Semiconductor, Raises Price Target to $100

Related Posts

Citigroup Maintains Buy on Instructure Holdings, Raises Price Target to $32

Axsome Therapeutics Announces Plans To Resubmit AXS-07 NDA Based On Successful FDA Type A Meeting; No Additional Clinical Efficacy Or Safety Trials Have Been Requested By The FDA For A Resubmission Of The NDA

Chevron Reportedly Exploring Option To Sell East Texas Assets: Report

Chamath Palihapitiya Calls Out Warren Buffett’s Japanese Investments: Is He Throwing Shade Or Praising The Legendary Investor?